BioCardia sold 3.5M shares at $1.279 per share on June 5, 2026, raising $4.4M in net proceeds. The capital is intended to fund operations through Q1 2027 and support the company's Japan PMDA submission for its CardiAMP cell therapy platform.
BioCardia sold 3.5M shares at $1.279 per share on June 5, 2026, raising $4.4M in net proceeds. The capital is intended to fund operations through Q1 2027 and support the company's Japan PMDA submission for its CardiAMP cell therapy platform.